NO995036L - 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase Inhibitors - Google Patents
5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase InhibitorsInfo
- Publication number
- NO995036L NO995036L NO995036A NO995036A NO995036L NO 995036 L NO995036 L NO 995036L NO 995036 A NO995036 A NO 995036A NO 995036 A NO995036 A NO 995036A NO 995036 L NO995036 L NO 995036L
- Authority
- NO
- Norway
- Prior art keywords
- heterocyclyl
- heteroaryl
- aryl
- compound
- lower alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En metode for å inhibere adenosinkinase ved å administrere en forbindelse som har formelen hvori R1 og R2 er uavhengig valgt fra H, lavere alkyl, Cj-CjalkoksyCj-Cealkyl, aryl-C^-C,;.alkyl, -C (O) Cj-Cjalkyl, -C(O)aryl, -C(O)heterocyklyl eller kan forbindes med nitrogenet som de er bundet til, og danner en 5-7- leddet ring eventuelt inneholdende 1-2 ytterligere heteroatomer valgt fra O, N eller S; R3 er valgt fra gruppen bestående av lavere alkyl, lavere alkenyl, 2,avere alkynyl, cykloalkyl, aryl, arylalkyl, hetero- aryl, heterocyklyl, heteroarylalkyl eller heterocyklo- alkyl hvor heteroaryl- og heterocyklylgruppene er bundet direkte eller indirekte av et ringkarbonatom; R* er valgt fra gruppen bestående av lavere alkyl, lavere alkenyl, lavere alkynyl, cykloalkyl, aryl, arylalkyl, heteroaryl, heterocyklylheteroarylalkyl eller hetero- cykloalkyl; og en stiplet linje --- indikerer at en dobbeltbinding er eventuelt nærværende forutsatt at de riktige valenser opprettholdes, en farmasøytisk sammen- setning omfattende en terapeutisk effektiv mengde av en forbindelse som definert ovenfor i kombinasjon med en farmasøytisk akseptabel bærer, og en metode for å behandle cerebral iskemi, epilepsi, nocipersepsjon, inflammasjon og sepsis i et pattedyr i behov av slik behandling, omfattende å administrere til pattedyret en terapeutisk effektiv mengde av en forbindelse som definert ovenfor, en fremgangsmåte for å fremstille nevnte forbindelser, og forbindelser som har ovennevnte formel.A method of inhibiting adenosine kinase by administering a compound having the formula wherein R 1 and R 2 are independently selected from H, lower alkyl, C 1 -C 6 alkoxyC -C 1-4 alkyl, -C (O) aryl, -C (O) heterocyclyl or may be joined to the nitrogen to which they are attached and form a 5-7 membered ring optionally containing 1-2 additional heteroatoms selected from O, N or S ; R 3 is selected from the group consisting of lower alkyl, lower alkenyl, 2, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocycloalkyl wherein the heteroaryl and heterocyclyl groups are bonded directly or indirectly by a ring carbon atom; R * is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl heteroarylalkyl or heterocycloalkyl; and a dotted line --- indicating that a double bond is optionally present provided that the proper valences are maintained, a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound as defined above, a process for preparing said compounds, and compounds having the above formula .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83821697A | 1997-04-16 | 1997-04-16 | |
| PCT/US1998/007207 WO1998046605A1 (en) | 1997-04-16 | 1998-04-14 | 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO995036L true NO995036L (en) | 1999-10-15 |
| NO995036D0 NO995036D0 (en) | 1999-10-15 |
Family
ID=25276561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO995036A NO995036D0 (en) | 1997-04-16 | 1999-10-15 | 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase Inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0989986A1 (en) |
| JP (1) | JP2001520655A (en) |
| KR (1) | KR20010006509A (en) |
| CN (1) | CN1252070A (en) |
| AR (1) | AR012436A1 (en) |
| AU (1) | AU7108398A (en) |
| BG (1) | BG103842A (en) |
| BR (1) | BR9809055A (en) |
| CA (1) | CA2286909A1 (en) |
| CO (1) | CO4940446A1 (en) |
| HU (1) | HUP0001434A3 (en) |
| IL (1) | IL131618A0 (en) |
| NO (1) | NO995036D0 (en) |
| PL (1) | PL336304A1 (en) |
| SK (1) | SK141799A3 (en) |
| TR (1) | TR199902455T2 (en) |
| WO (1) | WO1998046605A1 (en) |
| ZA (1) | ZA983177B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| WO2002064594A2 (en) | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| MXPA04006882A (en) | 2002-01-17 | 2004-12-06 | Neurogen Corp | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin. |
| DE10335183A1 (en) * | 2003-07-30 | 2005-02-24 | Bayer Cropscience Ag | Fungicidal drug combinations |
| ATE449097T1 (en) * | 2005-07-21 | 2009-12-15 | Hoffmann La Roche | PYRIDOÄ2,3-DÜPYRIMIDINE-2,4-DIAMINE COMPOUNDS AS PTPIB INHIBITORS |
| US7910595B2 (en) * | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
| MX2010002258A (en) * | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Therapeutic isoxazole compounds. |
| CA2694401C (en) | 2007-08-31 | 2012-12-04 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
| DE102007061764A1 (en) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellated cyanopyridines and their use |
| MX2011008501A (en) * | 2009-02-26 | 2011-09-01 | Eisai R&D Man Co Ltd | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors. |
| US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
| US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CN110256420B (en) * | 2019-05-07 | 2020-04-28 | 江西中医药大学 | Tetrahydropyridopyrimidine derivatives, their preparation and use |
| CN110283171A (en) * | 2019-07-17 | 2019-09-27 | 鼎泰(南京)临床医学研究有限公司 | Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1998
- 1998-04-14 AU AU71083/98A patent/AU7108398A/en not_active Abandoned
- 1998-04-14 BR BR9809055-0A patent/BR9809055A/en not_active Application Discontinuation
- 1998-04-14 KR KR1019997009599A patent/KR20010006509A/en not_active Application Discontinuation
- 1998-04-14 SK SK1417-99A patent/SK141799A3/en unknown
- 1998-04-14 EP EP98918093A patent/EP0989986A1/en not_active Withdrawn
- 1998-04-14 TR TR1999/02455T patent/TR199902455T2/en unknown
- 1998-04-14 IL IL13161898A patent/IL131618A0/en unknown
- 1998-04-14 WO PCT/US1998/007207 patent/WO1998046605A1/en not_active Application Discontinuation
- 1998-04-14 CA CA002286909A patent/CA2286909A1/en not_active Abandoned
- 1998-04-14 HU HU0001434A patent/HUP0001434A3/en unknown
- 1998-04-14 CN CN98804151A patent/CN1252070A/en active Pending
- 1998-04-14 PL PL98336304A patent/PL336304A1/en unknown
- 1998-04-14 JP JP54408898A patent/JP2001520655A/en active Pending
- 1998-04-15 AR ARP980101733A patent/AR012436A1/en unknown
- 1998-04-15 ZA ZA983177A patent/ZA983177B/en unknown
- 1998-04-16 CO CO98020979A patent/CO4940446A1/en unknown
-
1999
- 1999-10-15 NO NO995036A patent/NO995036D0/en not_active Application Discontinuation
- 1999-10-29 BG BG103842A patent/BG103842A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA983177B (en) | 1999-01-22 |
| EP0989986A1 (en) | 2000-04-05 |
| CA2286909A1 (en) | 1998-10-22 |
| CN1252070A (en) | 2000-05-03 |
| HUP0001434A3 (en) | 2001-01-29 |
| IL131618A0 (en) | 2001-01-28 |
| TR199902455T2 (en) | 2000-01-21 |
| PL336304A1 (en) | 2000-06-19 |
| AR012436A1 (en) | 2000-10-18 |
| CO4940446A1 (en) | 2000-07-24 |
| BR9809055A (en) | 2000-08-08 |
| JP2001520655A (en) | 2001-10-30 |
| AU7108398A (en) | 1998-11-11 |
| KR20010006509A (en) | 2001-01-26 |
| SK141799A3 (en) | 2000-08-14 |
| HUP0001434A2 (en) | 2000-10-28 |
| BG103842A (en) | 2000-06-30 |
| WO1998046605A1 (en) | 1998-10-22 |
| NO995036D0 (en) | 1999-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO995036L (en) | 5,7-Disubstituted 4-Aminopyrido [2,3-d] Pyrimidine Compounds and Their Use as Adenosine Kinase Inhibitors | |
| EP3122747B1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| CA2876690C (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| RU2678990C1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| CA2927373C (en) | Processes for preparing dihydropyrimidine derivatives and intermediates thereof | |
| HUP0100348A2 (en) | Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates | |
| AR063351A1 (en) | DERIVATIVES OF PURINE AND CONDENSED PYRIMIDINS, COMPOSITION AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT TO INHIBIT THE HSP90 IN A CELL. | |
| CN114206339A (en) | Deuterated MK2 pathway inhibitors and methods of use thereof | |
| CA3081751A1 (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| NO20072115L (en) | Pharmaceutical compounds | |
| NO331068B1 (en) | Benzazepine derivatives for the treatment of neurological disorders. | |
| KR20090079257A (en) | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto | |
| EP2597087A1 (en) | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors | |
| KR920002603A (en) | Pyrazolo pyridine compound and preparation method thereof | |
| NO20060650L (en) | Quinazoline derivatives as angiogenesis inhibitors | |
| CO5540385A2 (en) | OXAZOL ARILPROPIONIC ACID CHIRAL DERIVATIVES, THEIR SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| CA2942599A1 (en) | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl] amides | |
| NO20002099L (en) | 6,11-bridged erythromycin derivative | |
| WO2023160572A1 (en) | Pyrazole derivative, pharmaceutical composition, and use | |
| CA2042113A1 (en) | Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors | |
| NO179974C (en) | Analogous Process for Preparing Therapeutically Active Piperidine Compounds | |
| FI104070B1 (en) | A process for the preparation of therapeutically useful pyridine and imidazole derivatives | |
| SK164397A3 (en) | Method for preparing n-monosubstituted and n,n'-disubstituted unsymmetrical cyclic ureas | |
| RU2005100761A (en) | AMIDO SUBSTITUTED Xanthine derivatives possessing modulatory activity in relation to glucose biosynthesis from non-carbohydrate substrates | |
| EP3746444B1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |